CIMZIA PACKAGE INSERT PDF

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions 5. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Author:Fejas Vushicage
Country:Syria
Language:English (Spanish)
Genre:Software
Published (Last):5 August 2019
Pages:338
PDF File Size:13.62 Mb
ePub File Size:17.13 Mb
ISBN:654-8-41425-405-7
Downloads:34929
Price:Free* [*Free Regsitration Required]
Uploader:Mazshura



How is this drug used? What is the mechanism of action? How is Cimzia given administered? The specific schedule and dose depend on which condition is being treated. Cimzia is not suitable for children. How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Cimzia.

Patients will especially be monitored for tuberculosis as serious infections have happened in patients taking Cimzia. Your healthcare provider should test you for TB before starting treatment.

What are some of the less common but potentially serious side effects of Cimzia? This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment.

Patients should check with their physician about any side effects that continue or are bothersome. Are there any special warnings or precautions patients should be aware of before starting treatment? Before starting Cimzia, tell your healthcare provider about all of your medical conditions, including if you:. What should patients be aware of after treatment with Cimzia?

After starting Cimzia, any sign of infection including a fever, cough, flu-like symptoms, or open cuts or sores on your body, call your healthcare provider right away. Cimzia can make you more likely to get infections or make any infection that you may have worse.

Cimzia is a medicine that affects your immune system and can lower your ability to fight infections. Serious infections have occurred in patients taking Cimzia, including tuberculosis TB and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. When should patients notify their physician? The following could be symptoms of heart failure, allergic reactions, Hepatits B reactivation, nervous system problems, blood problems, and immune reactions.

Your healthcare provider should be called immediately if you experience:. Tell your healthcare provider if you notice any changes in the appearance of your skin, including growths on your skin, during or after treatment with Cimzia. A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.

A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug.

If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy. The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice.

Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician. As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care. In order to prevent any unnecessary risk to our patient population, the providers at Hematology Oncology Associates of Fredericksburg HOAF have agreed to incorporate virtual visits when appropriate.

What are the most common side effects of treatment with Cimzia? Upper respiratory tract infections flu, cold Rash Urinary tract infection What are some of the less common but potentially serious side effects of Cimzia? Heart failure Hepatitis B virus reactivation in patients who carry the virus in their blood New or worsening nervous system problems Blood problems Immune reactions including a lupus-like syndrome This is not a complete list of side effects.

Before starting Cimzia, tell your healthcare provider about all of your medical conditions, including if you: Have an infection. Have or have had any type of cancer. Have congestive heart failure. Have seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis.

Are scheduled to receive a vaccine. Do not receive a live vaccine while taking Cimzia. Are allergic to any of the ingredients in Cimzia. Are pregnant or planning to become pregnant. It is not known if Cimzia will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while receiving Cimzia. Are breastfeeding or plan to breastfeed.

It is not known if Cimzia passes into your breast milk. You and your healthcare provider should decide if you will receive Cimzia or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Additional warnings regarding cancer while taking TNF blocker medicines: The chances of getting lymphoma may increase.

People with RA, especially severe RA, may have a higher chance of lymphoma. A rare type of cancer called hepatosplenic T-cell lymphoma may occur. The chance of developing certain kinds of skin cancer may increase. What is a package insert? Important Limitations of Use The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. Quick Links. Saturday - Sunday Closed.

Friday AM - PM. Fredericksburg: Empire Court Fredericksburg, Virginia Phone: Fax:

FISIOPATOLOGIA DE LA DISMENORREA PDF

Dosing Information

How is this drug used? What is the mechanism of action? How is Cimzia given administered? The specific schedule and dose depend on which condition is being treated. Cimzia is not suitable for children.

SPYDERCO SHARPMAKER INSTRUCTIONS PDF

New Instructions from HOAF on Telehealth

Choose an option below to see the recommended CIMZIA dosing schedule for the prefilled syringe or the lyophilized powder for reconstitution. The dosing schedule is the same for both prefilled syringe for self-administration and lyophilized powder for reconstitution and administration by a healthcare professional. Initial dosing covers the first month of injections, which are provided at the start of therapy at Week 0, Week 2, and Week 4. Each of these doses is mg, given subcutaneously as 2 separate injections of mg each. After initial dosing phase is complete for your RA patient, there are 2 maintenance dosing options available: One mg injection taken every 2 weeks or two mg injections taken every 4 weeks. After initial dosing phase is complete for your PsA patient, there are 2 maintenance dosing options available: One mg injection taken every 2 weeks or two mg injections taken every 4 weeks. After initial dosing phase is complete for your AS patient, there are 2 maintenance dosing options available: One mg injection taken every 2 weeks or two mg injections taken every 4 weeks.

Related Articles